These findings thus identified non-MHC-restricted γδ T cells as potent adjuvant facilitating subsequent antigen-specific CD8+ T-cell immunity against tumour cells, including breast CSC-like cells, through their secretion of IFN-γ. The gene discussed is CD8A; the disease is neoplasm.